Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Care Bare Rx vs Luma Health Co

Care Bare Rx
Graded #43

Level

vs
Luma Health Co
Graded #59

Level

The verdict

Too close to call — both grade 75/100 (C).

Care Bare Rx and Luma Health Co land on the same WeighScore, so neither clears the other on our six graded dimensions. Care Bare Rx sits one line higher on the board (#43 vs #59) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLuma Health Co +1
68
69
Dose & formulationCare Bare Rx +25
94
69
Clinical oversightLuma Health Co +9
74
83
Labs & monitoringLuma Health Co +35
62
97
FulfillmentCare Bare Rx +8
78
70
Contract termsCare Bare Rx +17
72
55
Care Bare Rx · left barLuma Health Co · right bar

The numbers

MetricCare Bare RxLuma Health Co
WeighScore75/10075/100
GradeCC
Scorecard rank#43#59
SemaglutideFrom $199/mo (shared weight-loss price)$120/mo (plus a separate fee, compounded)
TirzepatideFrom $199/mo (shared weight-loss price)$180/mo (compounded)
CoverageMulti-state30 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Care Bare Rx

Graded #43 · C

Strengths

  • Oral tirzepatide as well as injectable — rare on this board
  • Brand Ozempic (from $705/mo) and oral Rybelsus beside the compounded line
  • LegitScript certified and HIPAA compliant
  • One platform if you also want hair, TRT, sexual health or NAD+

Where it loses points

  • The advertised "from $199/mo" is one figure shared across all weight-loss treatments — neither molecule priced separately
  • Per-dose pricing is quiz-gated, so a titrated cost cannot be modelled beforehand
  • No named clinicians, founding year or parent company disclosed
  • Compounded medication is not FDA-approved the way brand Ozempic, Wegovy, or Zepbound are
Luma Health Co

Graded #59 · C

Strengths

  • Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
  • No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
  • Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
  • Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
  • HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission

Where it loses points

  • Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
  • Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
  • No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
  • Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
  • Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard